National trends in ED lacerations between 1992 and 2002
Abstract
OBJECTIVE: National estimates of the number of lacerations are based on the number of wounds cared for in the emergency department (ED). However, this number includes wounds other than lacerations. We estimated the number and characteristics of lacerations treated in the United States between 1992 and 2002.
METHODS: The design used was secondary analysis of National Hospital Ambulatory Medical Care Survey (a weighted sample of ED encounters). Encounters with a laceration recorded as 1 of the 3 diagnosis codes (870-897) of the International Classification of Diseases, Ninth Revision, Clinical Modification for the visit were included. Data collection included demographics, wound location, insurance status, procedures performed, type of practitioner, and pain severity. For data analysis, the National Hospital Ambulatory Medical Care Survey databases for 1992 to 2002 were downloaded from its Web site and imported into SPSS 12.0 (SPSS, Chicago, Ill) for analysis. National estimates were obtained using assigned patient visit weights. Descriptive statistics were calculated, and group comparisons were performed with chi(2) tests using unweighted data. Rates were calculated using population data from the US census.
RESULTS: There were 300715 patient encounters sampled from nearly 400 EDs resulting in an estimated 1.08 billion ED visits between 1992 and 2002. In the sample, 24755 patients (8.2%) had lacerations resulting in an estimated 90 million lacerations. Although the number of…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.